Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

TY - JOUR

T1 - Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

AU - Ndhlovu, Lishomwa C.

AU - Umaki, Tracie

AU - Chew, Glen M.

AU - Chow, Dominic C.

AU - Agsalda, Melissa

AU - Kallianpur, Kalpana J.

AU - Paul, Robert

AU - Zhang, Guangxiang

AU - Ho, Erika

AU - Hanks, Nancy

AU - Nakamoto, Beau

AU - Shiramizu, Bruce T.

AU - Shikuma, Cecilia M.

N1 - Lishomwa C. Ndhlovu Tracie Umaki Glen M. Chew Dominic C. Chow Melissa Agsalda Kalpana J. Kallianpur Robert Paul Guangxiang Zhang Erika Ho Nancy Hanks Beau Nakamoto Bruce T. Shiramizu Cecilia M. Shikuma HIV-associated neurocognitive disorders (HAND) continues to be prevalent (30-50 %) despite plasma HIV-RNA suppression with combination antiretroviral therapy (cART).

PY - 2014/12/1

Y1 - 2014/12/1

UR - https://rd.springer.com/content/pdf/10.1007%2Fs13365-014-0279-x.pdf

U2 - 10.1007/s13365-014-0279-x

DO - 10.1007/s13365-014-0279-x

M3 - Article

VL - 20

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

ER -